CA2754592A1 - Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions - Google Patents

Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions Download PDF

Info

Publication number
CA2754592A1
CA2754592A1 CA2754592A CA2754592A CA2754592A1 CA 2754592 A1 CA2754592 A1 CA 2754592A1 CA 2754592 A CA2754592 A CA 2754592A CA 2754592 A CA2754592 A CA 2754592A CA 2754592 A1 CA2754592 A1 CA 2754592A1
Authority
CA
Canada
Prior art keywords
immunogenic composition
drug
nicotine
signal peptide
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2754592A
Other languages
English (en)
French (fr)
Inventor
William Henry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2754592A1 publication Critical patent/CA2754592A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2754592A 2009-03-09 2010-03-09 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions Abandoned CA2754592A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20962909P 2009-03-09 2009-03-09
US61/209,629 2009-03-09
PCT/EP2010/052997 WO2010103017A2 (en) 2009-03-09 2010-03-09 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions

Publications (1)

Publication Number Publication Date
CA2754592A1 true CA2754592A1 (en) 2010-09-16

Family

ID=42555592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2754592A Abandoned CA2754592A1 (en) 2009-03-09 2010-03-09 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions

Country Status (9)

Country Link
US (1) US20120100171A1 (enExample)
EP (1) EP2405943A2 (enExample)
JP (1) JP2012519724A (enExample)
KR (1) KR20120022760A (enExample)
CN (1) CN102427828A (enExample)
CA (1) CA2754592A1 (enExample)
MX (1) MX2011009359A (enExample)
RU (1) RU2011140858A (enExample)
WO (1) WO2010103017A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730328C (en) * 2008-09-03 2015-03-31 Board Of Trustees Of Michigan State University Immunogenic escherichia coli heat stable enterotoxin
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
US10160789B2 (en) 2011-03-14 2018-12-25 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
US10758605B2 (en) 2015-06-29 2020-09-01 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US20210277071A1 (en) * 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
CN113825984B (zh) * 2019-05-20 2024-08-13 美国西门子医学诊断股份有限公司 用于检测免疫测定中由多半抗原试剂的不完全递送引起的异常结果的方法
EP3993836A1 (en) * 2019-07-03 2022-05-11 Intervet International B.V. Conjugated deoxynivalenol to protect against mycotoxicosis
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4883761A (en) 1986-03-25 1989-11-28 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
HU216017B (hu) 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US20020032316A1 (en) 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
FR2768747B1 (fr) 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
CN1231586C (zh) * 2003-04-15 2005-12-14 中国科学院微生物研究所 一种多形汉逊酵母表达重组霍乱毒素b亚单位基因及其应用
GB0325494D0 (en) 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system

Also Published As

Publication number Publication date
KR20120022760A (ko) 2012-03-12
JP2012519724A (ja) 2012-08-30
US20120100171A1 (en) 2012-04-26
RU2011140858A (ru) 2013-04-20
WO2010103017A2 (en) 2010-09-16
CN102427828A (zh) 2012-04-25
MX2011009359A (es) 2011-12-16
EP2405943A2 (en) 2012-01-18
WO2010103017A3 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
US20120100171A1 (en) Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
EP1024834B1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US11739054B2 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
EP1329226B1 (en) Hapten-Carrier Conjugates for use in Drug Abuse Therapy
WO1998014216A9 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
ES2287379T3 (es) Conjugados de hapteno-transportador para usar en terapia del abuso de drogas.
US20060058220A1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO2011000889A1 (en) Topical vaccine formulations and methods of treating drug addiction using same
Romano et al. A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl
HK1027293B (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
KR20000048780A (ko) 약물남용 치료시에 사용되는 불완전항원-담체 포합체 및 상기 포합체의 제조방법
HK1110794A (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
HK1103035A (en) Hapten-carrier conjugates for use in drug-abuse therapy (cocaine)

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150310